Activation of HIV-1-specific immune responses to an HIV-1 vaccine constructed from a replication-defective adenovirus vector using various combinations of immunization protocols.
We constructed a recombinant replication defective adenovirus vector containing the env gene (Ad-Bal) derived from macrophage-trophic HIV-1 (HIV-1 Bal). We then immunized mice with this vector using several administration routes and protocols, and examined the immune response. When the Ad-Bal viral vector (over 1 x 10(7) pfu) was injected subcutaneously, both humoral and cell-mediated immunities were induced. However, immune response induced by the Ad-Bal vector alone was weaker than that induced by the recombinant vaccinia viral vector. We then employed the following three immunization protocols: (l) DNA vaccination followed by immunization with the Ad-Bal; (2) vaccination using the Ad-Bal vector followed by DNA vaccination; and (3) DNA vaccination followed by Ad-Bal infection and passive transfer of dendritic cells (DCs) infected with the Ad-Bal. Among the three protocols, the last gave the strongest humoral and cell-mediated immunity. These results suggest that the combination of DNA vaccination, Ad-Bal vector infection and passive transfer of Ad-Bal-infected DCs can induce strong immunity against HIV-1 Bal.
Yoshida
T
T
Department of Orthopaedic Surgery, Yokohama City University School of Medicine, Yokohama, Japan.
Okuda
K
K
Xin
K Q
KQ
Tadokoro
K
K
Fukushima
J
J
Toda
S
S
Hagiwara
E
E
Hamajima
K
K
Koshino
T
T
Saito
T
T
D016915:AIDS Vaccines / Q000276:immunology*; D000260:Adenoviruses, Human; D000595:Amino Acid Sequence; D000818:Animals; D003713:Dendritic Cells / Q000276:immunology; D005260:Female; D005822:Genetic Vectors; D015483:HIV Antibodies / Q000096:biosynthesis; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000276:immunology; D007116:Immunization, Passive; D051379:Mice; D008807:Mice, Inbred BALB C; D008969:Molecular Sequence Data; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D014611:Vaccination / Q000379:methods; D014614:Vaccines, Synthetic / Q000276:immunology*; D014779:Virus Replication
D016915:AIDS Vaccines; D015483:HIV Antibodies; D014614:Vaccines, Synthetic